DK3509581T3 - Formuleringer af (r)-2-amino-3-phenylpropylcarbamat - Google Patents

Formuleringer af (r)-2-amino-3-phenylpropylcarbamat Download PDF

Info

Publication number
DK3509581T3
DK3509581T3 DK17849426.6T DK17849426T DK3509581T3 DK 3509581 T3 DK3509581 T3 DK 3509581T3 DK 17849426 T DK17849426 T DK 17849426T DK 3509581 T3 DK3509581 T3 DK 3509581T3
Authority
DK
Denmark
Prior art keywords
phenylpropylcarbamate
formulations
amino
Prior art date
Application number
DK17849426.6T
Other languages
English (en)
Inventor
Clark Patrick Allphin
Edwin Gerard Walsh
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61281851&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3509581(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Application granted granted Critical
Publication of DK3509581T3 publication Critical patent/DK3509581T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
DK17849426.6T 2016-09-06 2017-09-06 Formuleringer af (r)-2-amino-3-phenylpropylcarbamat DK3509581T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383818P 2016-09-06 2016-09-06
US15/695,913 US10195151B2 (en) 2016-09-06 2017-09-05 Formulations of (R)-2-amino-3-phenylpropyl carbamate
PCT/US2017/050221 WO2018048862A1 (en) 2016-09-06 2017-09-06 Formulations of ( r)-2-amino-3-phenylpropyl carbamate

Publications (1)

Publication Number Publication Date
DK3509581T3 true DK3509581T3 (da) 2023-01-09

Family

ID=61281851

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17849426.6T DK3509581T3 (da) 2016-09-06 2017-09-06 Formuleringer af (r)-2-amino-3-phenylpropylcarbamat

Country Status (19)

Country Link
US (6) US10195151B2 (da)
EP (1) EP3509581B1 (da)
JP (1) JP7148498B2 (da)
KR (1) KR102464646B1 (da)
CN (1) CN109906078B (da)
AU (1) AU2017324855B2 (da)
CA (1) CA3036068A1 (da)
CL (1) CL2019000571A1 (da)
DK (1) DK3509581T3 (da)
ES (1) ES2937795T3 (da)
FI (1) FI3509581T3 (da)
IL (1) IL265193B (da)
MX (1) MX2019002606A (da)
MY (1) MY197631A (da)
PH (1) PH12019500494A1 (da)
RU (1) RU2764576C2 (da)
SA (1) SA519401246B1 (da)
SG (1) SG11201901996UA (da)
WO (1) WO2018048862A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
EP3630072A4 (en) * 2017-06-02 2021-03-10 Jazz Pharmaceuticals Ireland Limited METHODS AND COMPOSITIONS FOR TREATMENT OF EXCESSIVE Drowsiness
CN111094238B (zh) 2017-07-31 2023-06-09 杰资制药爱尔兰有限公司 氨基甲酰基苯丙氨醇类似物及其用途
JP7553453B2 (ja) 2019-03-01 2024-09-18 フラメル アイルランド リミテッド 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物
US20240041817A1 (en) * 2020-03-19 2024-02-08 Axsome Malta Ltd. Methods of providing solriamfetol therapy to subjects with impaired renal function
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (ko) * 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
MX2024002483A (es) * 2021-09-03 2024-03-14 Axsome Therapeutics Metodos y composiciones para mejorar biomarcadores asociados con riesgo cardiovascular usando carbamato de (r)-2-amino-3-fenilpropi lo.
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
WO2024145545A2 (en) * 2022-12-30 2024-07-04 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
WO2024194718A1 (en) 2023-03-22 2024-09-26 Unichem Laboratories Limited A stable pharmaceutical composition and process for preparing thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US81970A (en) 1868-09-08 Edgar jo h n a m
US246874A (en) 1881-09-13 Crank-axle
US350098A (en) 1886-10-05 Salvator
US111027A (en) 1871-01-17 Improvement in hot-air furnaces
DE2939660A1 (de) 1979-09-29 1981-04-16 Basf Ag, 6700 Ludwigshafen Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
ZA943862B (en) 1993-06-10 1995-12-04 Lilly Co Eli Method of preventing emesis and treating sexual dysfunction using tetrahydrobenz[cd] indole-6-carboxamides
KR100197892B1 (ko) * 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
JP4068154B2 (ja) 1996-10-10 2008-03-26 エス ケー コーポレイション Ｏ―カルバモイル―フェニルアラニノール化合物とその薬剤学的に有用な塩及びその製造方法
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
CA2355293C (en) 1998-12-23 2005-08-16 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
JP4276837B2 (ja) 2001-02-27 2009-06-10 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 双極性障害の予防もしくは治療における使用のためのカルバメート化合物
US7078436B2 (en) 2001-02-27 2006-07-18 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating anxiety disorders
DE60221670T2 (de) 2001-02-27 2008-04-30 Ortho-Mcneil Pharmaceutical, Inc. Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
US6680299B2 (en) 2001-07-27 2004-01-20 Enanta Pharmaceuticals, Inc. 4'-substituted leucomycins
MXPA05001184A (es) 2002-07-29 2005-09-12 Johnson & Johnson Formulaciones y formas de dosificacion para administracion controlada de topiramato.
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
US20050203130A1 (en) 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CN101132787A (zh) 2004-10-28 2008-02-27 Sk株式会社 抑郁的辅助疗法
RU2417077C2 (ru) 2005-06-08 2011-04-27 Ск Холдингз Ко., Лтд. Способ лечения чрезмерной дневной сонливости (варианты)
CA2612672C (en) 2005-06-22 2014-10-14 Janssen Pharmaceutica, N.V. Treatment for sexual dysfunction
AU2005335241B9 (en) 2005-07-26 2012-12-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating substance-related disorders
JP2010506845A (ja) * 2006-10-13 2010-03-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ フェニルアルキルアミノカルバメート組成物
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
JP6095366B2 (ja) 2009-06-22 2017-03-15 エスケー バイオファーマシューティカルズ カンパニー リミテッド 疲労を治療又は予防するための方法
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
AU2010316106B2 (en) 2009-11-06 2015-10-22 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
KR101783633B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 섬유근육통 증후군의 치료 방법
JP5925766B2 (ja) 2010-05-04 2016-05-25 ジャズ、ファーマシューティカルズ、インコーポレイテッドＪａｚｚ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． γ−ヒドロキシ酪酸塩の即時放出製剤および剤形
EP2392325A1 (en) 2010-06-04 2011-12-07 Universitätsklinikum Münster Compounds for the prevention and/or treatment of osteoarthrosis
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
CA2905457A1 (en) 2013-03-13 2014-10-09 Aerial Biopharma, Llc Treatment of cataplexy
KR20210152011A (ko) 2013-07-12 2021-12-14 에스케이바이오팜 주식회사 금연의 촉진
ES2812586T3 (es) 2013-07-18 2021-03-17 Jazz Pharmaceuticals Ireland Ltd Tratamiento para la obesidad
TWI698415B (zh) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
JP6466792B2 (ja) 2015-07-03 2019-02-06 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
EP3630072A4 (en) 2017-06-02 2021-03-10 Jazz Pharmaceuticals Ireland Limited METHODS AND COMPOSITIONS FOR TREATMENT OF EXCESSIVE Drowsiness
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function

Also Published As

Publication number Publication date
EP3509581A1 (en) 2019-07-17
US20180064652A1 (en) 2018-03-08
US10512609B2 (en) 2019-12-24
US10195151B2 (en) 2019-02-05
JP7148498B2 (ja) 2022-10-05
IL265193A (en) 2019-05-30
US20230078754A1 (en) 2023-03-16
SG11201901996UA (en) 2019-04-29
IL265193B (en) 2021-04-29
RU2019110127A (ru) 2020-10-08
PH12019500494A1 (en) 2019-06-03
EP3509581A4 (en) 2020-04-08
US20210205227A1 (en) 2021-07-08
AU2017324855A1 (en) 2019-03-28
EP3509581B1 (en) 2022-11-09
CN109906078B (zh) 2022-09-13
MX2019002606A (es) 2019-09-18
AU2017324855B2 (en) 2022-02-17
FI3509581T3 (fi) 2023-01-31
KR20190104510A (ko) 2019-09-10
KR102464646B1 (ko) 2022-11-08
ES2937795T3 (es) 2023-03-31
CN109906078A (zh) 2019-06-18
US20240285538A1 (en) 2024-08-29
US11439597B2 (en) 2022-09-13
CL2019000571A1 (es) 2020-02-21
MY197631A (en) 2023-06-29
CA3036068A1 (en) 2018-03-15
SA519401246B1 (ar) 2023-12-15
RU2764576C2 (ru) 2022-01-18
WO2018048862A1 (en) 2018-03-15
US11998639B2 (en) 2024-06-04
US20200085748A1 (en) 2020-03-19
RU2019110127A3 (da) 2020-12-16
US20190117578A1 (en) 2019-04-25
JP2019533640A (ja) 2019-11-21

Similar Documents

Publication Publication Date Title
DK3509581T3 (da) Formuleringer af (r)-2-amino-3-phenylpropylcarbamat
DK3688162T3 (da) Formuleringer
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
DK3468966T3 (da) Inhibitorer af menin-mll-interaktionen
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3554240T3 (da) Kombinationer af aktive forbindelser
DK3439635T3 (da) Formuleringer til behandling af fast tumor
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3368014T3 (da) Nye formuleringer af cannabinoider
DK3180331T3 (da) Polymorfer af selinexor
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
DK3102555T3 (da) Sammensætninger af forbindelser og anvendelser deraf
DK3668851T3 (da) Fremgangsmåde til fremstilling af thiocarbonater
DK3259349T3 (da) Dehydrogenase-katalyseret fremstilling af FDCA
DK3448846T3 (da) Syntese af indazoler
DK3798222T3 (da) Krystallinsk form af den frie base af lorlatinib
DK3512857T3 (da) Spiro-bicykliske inhibitorer af menin-mll-interaktion
DK3457851T3 (da) Derivater af sobetirom
DK3285756T3 (da) Formuleringer af l-ornithinphenylacetat
DK3448849T3 (da) Syntese af indazoler
DK3943070T3 (da) Langtidsvirkende formuleringer af bedaquilin
DK3220891T3 (da) Sublingual formulering af riluzol
DK3307267T3 (da) Behandling af multipel sklerose
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation